TY - JOUR
T1 - Imbalance between CaM kinase II and calcineurin activities impairs caffeine-induced calcium release in hypertrophic cardiomyocytes
AU - Lu, Ying Mei
AU - Shioda, Norifumi
AU - Han, Feng
AU - Moriguchi, Shigeki
AU - Kasahara, Jiro
AU - Shirasaki, Yasufumi
AU - Qin, Zheng Hong
AU - Fukunaga, Kohji
N1 - Funding Information:
This work was supported in part by grants-in-aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan (19390150 to K.F.) and the Smoking Research Foundation (to K.F.).
PY - 2007/12/15
Y1 - 2007/12/15
N2 - Cardiac hypertrophy impairs Ca2+ handling in the sarcoplasmic reticulum, thereby impairing cardiac contraction. To identify the mechanisms underlying impaired Ca2+ release from the sarcoplasmic reticulum in hypertrophic cardiomyocytes, we assessed Ca2+-dependent signaling and the phosphorylation of phospholamban, which regulates Ca2+ uptake during myocardial relaxation and is in turn regulated by Ca2+/calmodulin-dependent protein kinase II (CaMKII) and calcineurin. In cultured rat cardiomyocytes, treatment with endothelin-1, angiotensin II, and phenylephrine-induced hypertrophy and increased CaMKII autophosphorylation and calcineurin expression. The calcineurin level reached its maximum at 72 h and remained elevated for at least 96 h after endothelin-1 or angiotensin II treatment. By contrast, CaMKII autophosphorylation, phospholamban phosphorylation, and caffeine-induced Ca2+ mobilization all peaked 48 h after these treatments. By 96 h after treatment, CaMKII autophosphorylation and phospholamban phosphorylation had returned to baseline, and caffeine-induced Ca2+ mobilization was impaired relative to baseline. A similar biphasic change was observed in dystrophin levels in endothelin-1-induced hypertrophic cardiomyocytes, and treatment with the novel CaM antagonists DY-9760e and DY-9836 significantly inhibited the hypertrophy-induced dystrophin breakdown. Taken together, the abnormal Ca2+ regulation in cardiomyocytes following hypertrophy is in part mediated by an imbalance in calcineurin and CaMKII activities, which leads to abnormal phospholamban activity.
AB - Cardiac hypertrophy impairs Ca2+ handling in the sarcoplasmic reticulum, thereby impairing cardiac contraction. To identify the mechanisms underlying impaired Ca2+ release from the sarcoplasmic reticulum in hypertrophic cardiomyocytes, we assessed Ca2+-dependent signaling and the phosphorylation of phospholamban, which regulates Ca2+ uptake during myocardial relaxation and is in turn regulated by Ca2+/calmodulin-dependent protein kinase II (CaMKII) and calcineurin. In cultured rat cardiomyocytes, treatment with endothelin-1, angiotensin II, and phenylephrine-induced hypertrophy and increased CaMKII autophosphorylation and calcineurin expression. The calcineurin level reached its maximum at 72 h and remained elevated for at least 96 h after endothelin-1 or angiotensin II treatment. By contrast, CaMKII autophosphorylation, phospholamban phosphorylation, and caffeine-induced Ca2+ mobilization all peaked 48 h after these treatments. By 96 h after treatment, CaMKII autophosphorylation and phospholamban phosphorylation had returned to baseline, and caffeine-induced Ca2+ mobilization was impaired relative to baseline. A similar biphasic change was observed in dystrophin levels in endothelin-1-induced hypertrophic cardiomyocytes, and treatment with the novel CaM antagonists DY-9760e and DY-9836 significantly inhibited the hypertrophy-induced dystrophin breakdown. Taken together, the abnormal Ca2+ regulation in cardiomyocytes following hypertrophy is in part mediated by an imbalance in calcineurin and CaMKII activities, which leads to abnormal phospholamban activity.
KW - Calcineurin
KW - CaMKII
KW - Cardiomyocyte
KW - DY-9760e
KW - Hypertrophy
KW - Phospholamban
UR - http://www.scopus.com/inward/record.url?scp=36049031562&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=36049031562&partnerID=8YFLogxK
U2 - 10.1016/j.bcp.2007.08.022
DO - 10.1016/j.bcp.2007.08.022
M3 - Article
C2 - 17888407
AN - SCOPUS:36049031562
SN - 0006-2952
VL - 74
SP - 1727
EP - 1737
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 12
ER -